Public co-investment in first-in-class phase 1 with a royalty return
A public investment fund would match private money in the riskiest early trials of truly new cancer drugs, taking a small share of future royalties so that taxpayers gain when the bets pay off.
A sovereign or supranational fund co-invests one-to-one alongside private investors in phase 1 trials of assets that meet a first-in-class test (novel target or novel mechanism with no approved analogue), in exchange for a royalty stake or equity. The fund's return is portfolio-level and long-term; its purpose is to lower the private cost of capital for novel mechanisms relative to me-too assets. The Cancer Prevention and Research Institute of Texas (CPRIT) and the California Institute for Regenerative Medicine (CIRM) show public bodies can invest in translational biotech with revenue-sharing and attract companies; the EU's Innovative Health Initiative and BARDA venture arms are related models.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
Pages like this
not linked directly; found by shared links- IdeaMilestone-based venture philanthropy with royalties recycled into the pipeline
Shares A diversified royalty pool that finances academic phase 1 trials across fifty assets, A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
- IdeaMilestone prizes for first-in-class mechanisms reaching human proof of concept
Shares Government reinsurance for phase 2 failures of first-in-class cancer drugs, Incentives reward me-too drugs and marginal gains.
- IdeaSet aside 3% of grant budgets to replicate findings before translation
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
- IdeaA funded organoid and PDX panel as the go/no-go gate before IND-enabling money
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
- IdeaA phase 0 fund to test academic compounds in humans with microdoses and imaging
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
- IdeaRegional translational institutes with academic GMP suites and IND teams
Shares A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks, The valley of death between lab and product.
- PersonBrian Druker
Shares The valley of death between lab and product, Incentives reward me-too drugs and marginal gains.
- IdeaA non-profit pharmaceutical company for the cancers markets ignore
Shares The valley of death between lab and product, Incentives reward me-too drugs and marginal gains.